This systematic review evaluated the effectiveness and cost-effectiveness of various androgen suppression therapies for advanced prostate cancer, comparing monotherapy options such as orchiectomy, luteinizing hormone-releasing hormone (LHRH) agonists, and antiandrogens to combined androgen blockade (CAB), while also examining the timing of therapy initiation (immediate vs. deferred). The study found that
